Funding for this research was provided by:
B&A Therapeutics, Neurochlore
Article History
Received: 1 December 2022
Accepted: 23 June 2023
First Online: 14 July 2023
Competing interests
: C.H. and N.L. are employed by B&A Therapeutics a startup dedicated to treat Parkinson’s disease and S.E. by Neurochlore, a startup dedicated to the development of treatments for children with autism. C.H. is shareholder of B&A Therapeutics.